Project Summary: Few treatment options are available for T cell leukemias and lymphomas, collectively called T cell cancers that affect ~100,000 patients worldwide each year. The current proposal will generate new antibodies attached to drugs and toxins that kill the T cell cancers. Importantly, the antibodies will preserve enough healthy T cells to maintain a functioning immune system. These modified antibodies may improve patient outcome and limit side effects associated with traditional chemotherapies. https://bloodcancerunited.org/research/award/tcr-directed-immunotoxins-and-antibody-drug-conjugates-treatment-t-cell-malignancies

https://bloodcancerunited.org/award-recipient/suman-paul